Anxiety Reduction in TAVI Using Virtual Reality Trial (ART-VR)
Primary Purpose
Aortic Stenosis, Severe, Anxiety
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Virtual Reality Immersion
Sponsored by
About this trial
This is an interventional treatment trial for Aortic Stenosis, Severe focused on measuring Immersive Virtual Reality, Procedural Anxiety, TAVR
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Symptomatic severe aortic stenosis
- Indication for transfemoral TAVI under local anaesthesia per local heart team consensus
- Patient is able to understand and sign written informed consent
- Patient speaks Dutch, German or English
Exclusion Criteria:
- Need for emergent TAVI
- Need for planned concomitant cardiac intervention during index procedure
- History of TAVI under local anesthesia/conscious sedation
- Chronic use of benzodiapines, opioids, pregabalin or antidepressants
- History of opioid use (within 8-30 days prior to randomization)
- Claustrophobia
- Any psychiatric illness diagnosed by a psychiatrist or psychologist
- Blindness or severe visual impairment despite visual aid (glasses, contact lenses)
- Epilepsy
- Extensive cognitive impairment (MMSE <21 or as diagnosed by geriatrician)
Sites / Locations
- Erasmus University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
VR-immersion
Non-VR control
Arm Description
Outcomes
Primary Outcome Measures
Procedural Anxiety
Procedural anxiety assessed on a visual analogue scale directly post-procedure. Range: 0 (no anxiety) to 10 (worst anxiety).
Secondary Outcome Measures
Change of Anxiety
Difference between pre-procedural and post-procedural anxiety visual analogue scale scores
Procedural Pain
Procedural pain assessed on a visual analogue scale directly post-procedure. Range: 0 (no pain) to 10 (worst pain).
Procedural Use of Sedatives
Procedural sedative use and dosage. Amount of benzodiazepine used in milligrams
Procedural Use of Analgesics
Procedural analgesic use and dosage. Amount of Lidocaine (or equivalent) used in milligrams
Patient Procedural Satisfaction
Procedural satisfaction assessed after 24hrs using for procedures under regional anaesthesia. Score assessed on a visual analogue scale. Range: 0 (not at all satisfied) to 10 (very satisfied).
Full Information
NCT ID
NCT05069987
First Posted
September 20, 2021
Last Updated
July 25, 2022
Sponsor
Erasmus Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05069987
Brief Title
Anxiety Reduction in TAVI Using Virtual Reality Trial
Acronym
ART-VR
Official Title
Anxiety Reduction in TAVI Using Virtual Reality Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 16, 2021 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
May 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The ART-VR Trial is an international multi-center, open label, randomized controlled trial evaluating the effect of an immersive VR environment on procedural anxiety in patients undergoing transfemoral aortic valve replacement (TAVR) under local anaesthesia.
Detailed Description
Virtual reality (VR) allows patients to be fully immerged in an engaging, interactive 3D environment. Its applications are broad and include treatment of phobias, stress-disorders, pain reduction. Recently, VR has been adopted in various medical procedures to reduce pre- and per-procedural anxiety. In TAVR, per-procedural VR immersion could potentially reduce patient anxiety leading to increased overall patient satisfaction. However, contemporary large scale, randomized evidence on VR application in TAVR is lacking.
The objective of this trial is to evaluate the effect of an immersive VR environment on procedural anxiety in patients undergoing TAVR under local anaesthesia in a randomized controlled setting. A total of 150 patients with severe aortic stenosis (AS) who undergo transfemoral TAVR under local aneasthesia will be included. The main study endpoint is procedural anxiety assessed on a visual analogue scale (VAS) directly post-procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Stenosis, Severe, Anxiety
Keywords
Immersive Virtual Reality, Procedural Anxiety, TAVR
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects will be randomly assigned, in a 1:1 ratio, to either procedural VR-immersion or non-VR control.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
VR-immersion
Arm Type
Experimental
Arm Title
Non-VR control
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
Virtual Reality Immersion
Intervention Description
An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax & Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
Primary Outcome Measure Information:
Title
Procedural Anxiety
Description
Procedural anxiety assessed on a visual analogue scale directly post-procedure. Range: 0 (no anxiety) to 10 (worst anxiety).
Time Frame
Immediately after the TAVR procedure
Secondary Outcome Measure Information:
Title
Change of Anxiety
Description
Difference between pre-procedural and post-procedural anxiety visual analogue scale scores
Time Frame
1 day (From directly before the TAVR procedure until directly after the TAVR procedure)
Title
Procedural Pain
Description
Procedural pain assessed on a visual analogue scale directly post-procedure. Range: 0 (no pain) to 10 (worst pain).
Time Frame
Immediately after the TAVR procedure
Title
Procedural Use of Sedatives
Description
Procedural sedative use and dosage. Amount of benzodiazepine used in milligrams
Time Frame
Up to 1 day (Depending on procedure duration)
Title
Procedural Use of Analgesics
Description
Procedural analgesic use and dosage. Amount of Lidocaine (or equivalent) used in milligrams
Time Frame
Up to 1 day (Depending on procedure duration)
Title
Patient Procedural Satisfaction
Description
Procedural satisfaction assessed after 24hrs using for procedures under regional anaesthesia. Score assessed on a visual analogue scale. Range: 0 (not at all satisfied) to 10 (very satisfied).
Time Frame
One day post procedure
Other Pre-specified Outcome Measures:
Title
Patient reported procedural Nausea and Vomiting
Description
Patient reported nausea and vomiting during the procedure (yes/no)
Time Frame
Up to 1 day (Depending on procedure duration)
Title
Admission time
Description
Time leaving cathlab until discharge
Time Frame
Up to 7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
Symptomatic severe aortic stenosis
Indication for transfemoral TAVI under local anaesthesia per local heart team consensus
Patient is able to understand and sign written informed consent
Patient speaks Dutch, German or English
Exclusion Criteria:
Need for emergent TAVI
Need for planned concomitant cardiac intervention during index procedure
History of TAVI under local anesthesia/conscious sedation
Chronic use of benzodiapines, opioids, pregabalin or antidepressants
History of opioid use (within 8-30 days prior to randomization)
Claustrophobia
Any psychiatric illness diagnosed by a psychiatrist or psychologist
Blindness or severe visual impairment despite visual aid (glasses, contact lenses)
Epilepsy
Extensive cognitive impairment (MMSE <21 or as diagnosed by geriatrician)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolas Van Mieghem, MD, PhD
Phone
+31107035260
Email
n.vanmieghem@erasmusmc.nl
Facility Information:
Facility Name
Erasmus University Medical Center
City
Rotterdam
State/Province
Zuid Holland
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Van Mieghem
Email
n.vanmieghem@erasmusmc.nl
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Anxiety Reduction in TAVI Using Virtual Reality Trial
We'll reach out to this number within 24 hrs